Skip to content

Allergan Announces FDA Approval of JUVÉDERM® XC Dermal Filler Formulated with Lidocaine

Allergan, Inc. (NYSE:AGN) announces the U.S. Food and Drug Administration's (FDA) approval of JUVÉDERM® XC, a new formulation of the currently FDA-approved JUVÉDERM® dermal filler and the latest advancement in hyaluronic acid (HA) dermal fillers. Allergan's new JUVÉDERM® formulation contains the local anesthetic lidocaine to provide patients with enhanced comfort during treatment of moderate to severe facial wrinkles and folds, such as the nasolabial folds (or "parentheses") that appear around the nose and mouth.

Read more here  >


        Allergan Announces FDA Approval of JUVÉDERM® XC Dermal Filler Formulated with Lidocaine

Global in reach. Specialized in focus.

Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully.

Our focus fosters deep engagement with medical specialists and we make it our business to listen closely to their needs so that together we can advance patient care. We combine this strategic focus with a diversified approach that enables us to follow our research and development into new specialty areas where unmet needs are significant.

In partnership with the medical community, we bring scientific excellence and rigor to deliver leading products that improve patient outcomes. And, we go above and beyond this to provide education and information, with the highest level of integrity, that helps patients to fully understand the choices available to them and make well-informed treatment decisions with their doctors. We know we are successful when doctors and patients place their trust in our products and our company, when our employees excel and when our efforts make a meaningful difference in the lives of the patients and communities we serve.

We are pleased to offer a number of leading products, including: BOTOX® (onabotulinumtoxinA), RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN® (bimatoprost ophthalmic solution) 0.03%, BOTOX® Cosmetic (onabotulinumtoxinA), the JUVÉDERM® family of dermal fillers, and the LAP-BAND® Adjustable Gastric Banding System. Throughout our Web site you can learn more about these and our full portfolio of products.

AGN NYSE
62.31 (0.2)
Volume 1,566,200

GLOBAL LOCATIONS

Learn about our worldwide locations.

  

NEWS & EVENTS

03.09.10BOTOX(R) (OnabotulinumtoxinA) Receives FDA Approval for Treatment of Upper Limb Spasticity in Adults
03.03.10Bristol-Myers Squibb and Allergan Enter Global Agreement on Investigational Neuropathic Pain Medicine
03.03.10Allergan Celebrates 20 Years of Approved Use of Botulinum Toxin Type A (BOTOX(R)) in Canada
More news